The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials

References

• AméJCSpenlehauerCde MurciaGThe PARP superfamilyBioessays200426888289315273990
   PubMed Web of Science ®Google Scholar
• SchiewerMJGoodwinJFHanSDual roles of PARP-1 promote cancer growth and progressionCancer Discov20122121134114922993403
   PubMed Web of Science ®Google Scholar
• WalshCSTwo decades beyond BRCA1/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapyGynecol Oncol2015137234335025725131
   PubMed Web of Science ®Google Scholar
• BrownJSKayeSBYapTAPARP inhibitors: the race is onBr J Cancer2016114771371527022824
   PubMed Web of Science ®Google Scholar
• AshworthAA synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repairJ Clin Oncol200826223785379018591545
   PubMed Web of Science ®Google Scholar
• FarmerHMccabeNLordCJTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature2005434703591792115829967
   PubMed Web of Science ®Google Scholar
• Pujade-LauraineELedermannJASelleFOlaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialLancet Oncol20171891274128428754483
   PubMed Web of Science ®Google Scholar
• BangYJXuRHChinKOlaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trialLancet Oncol201718121637165129103871
   PubMed Web of Science ®Google Scholar
• RobsonMImSASenkusEOlaparib for metastatic breast cancer in patients with a germline BRCA mutationN Engl J Med2017377652353328578601
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementInt J Surg20108533634120171303
   PubMed Web of Science ®Google Scholar
• JadadARMooreRACarrollDAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials19961711128721797
   PubMedGoogle Scholar
• DersimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials1986731771883802833
   PubMedGoogle Scholar
• LauJIoannidisJPSchmidCHQuantitative synthesis in systematic reviewsAnn Intern Med199712798208269382404
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
   PubMed Web of Science ®Google Scholar
• BeggCBMazumdarMOperating characteristics of a rank correlation test for publication biasBiometrics1994504108811017786990
   PubMed Web of Science ®Google Scholar
• EggerMDavey SmithGSchneiderMMinderCBias in meta-analysis detected by a simple, graphical testBMJ199731571096296349310563
   PubMed Web of Science ®Google Scholar
• BangYJImSALeeKWRandomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancerJ Clin Oncol201533333858386526282658
   PubMed Web of Science ®Google Scholar
• LedermannJHarterPGourleyCOlaparib maintenance therapy in platinum-sensitive relapsed ovarian cancerN Engl J Med2012366151382139222452356
   PubMed Web of Science ®Google Scholar
• KayeSBLubinskiJMatulonisUPhase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and PEGylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancerJ Clin Oncol201230437237922203755
   PubMed Web of Science ®Google Scholar
• OzaAMCibulaDBenzaquenAOOlaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialLancet Oncol2015161879725481791
   PubMed Web of Science ®Google Scholar
• WollPGauntPSteeleNSTOMP: a UK National Cancer Research Network randomised, double blind, multicentre phase II trial of olaparib as maintenance therapy in SCLCJ Thorac Oncol2017121 SupplS704S705
   PubMed Web of Science ®Google Scholar
• BaoZCaoCGengXEffectiveness and safety of poly(ADP-ribose) polymerase inhibitors in cancer therapy: a systematic review and meta-analysisOncotarget2016777629763926399274
   PubMedGoogle Scholar
• AlsopKFeredaySMeldrumCBRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study GroupJ Clin Oncol201230212654266322711857
   PubMed Web of Science ®Google Scholar
• ZhangSRoyerRLiSFrequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancerGynecol Oncol2011121235335721324516
   PubMed Web of Science ®Google Scholar
• MaloneKEDalingJRDoodyDRPrevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 yearsCancer Res200666168297830816912212
   PubMed Web of Science ®Google Scholar
• HodgsonDMasonHOplustilovaLActivity of the PARP inhibitor olaparib in ATM-deficient gastric cancer: from preclinical models to the clinicCancer Res20147419 Suppl2398
   Web of Science ®Google Scholar
• KubotaEWilliamsonCTYeRLow ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell linesCell Cycle201413132129213724841718
   PubMed Web of Science ®Google Scholar
• SchmittAKnittelGWelckerDATM deficiency is associated with sensitivity to PARP1- and ATR inhibitors in lung adenocarcinomaCancer Res201777113040305628363999
   PubMed Web of Science ®Google Scholar
• PerkhoferLSchmittARomero CarrascoMCATM deficiency generating genomic instability sensitizes pancreatic ductal adenocarcinoma cells to therapy-induced DNA damageCancer Res201777205576559028790064
   PubMed Web of Science ®Google Scholar
• KnittelGRehkämperTKorovkinaDTwo mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemiaNat Commun20178115328751718
   PubMedGoogle Scholar
• PatelAGFlattenKSSchneiderPAEnhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymesJ Biol Chem201228764198421022158865
   PubMed Web of Science ®Google Scholar
• MuraiJZhangYMorrisJRationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibitionJ Pharmacol Exp Ther2014349340841624650937
   PubMed Web of Science ®Google Scholar
• ZhouJXFengLJZhangXRisk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trialsDrug Des Devel Ther20171130093017
   PubMed Web of Science ®Google Scholar
• DirixLSwaislandHVerheulHMEffect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: results of two phase I open-label studiesClin Ther201638102286229927745744
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer InstituteNCCN guidelines for supportive care: cancer-related fatigue2015 Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#fatigueAccessed June 28, 2018
   Google Scholar
• BowerJECancer-related fatigue: mechanisms, risk factors, and treatmentsNat Rev Clin Oncol2014111059760925113839
   PubMed Web of Science ®Google Scholar
• KaufmanBShapira-FrommerRSchmutzlerRKOlaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutationJ Clin Oncol201533324425025366685
   PubMed Web of Science ®Google Scholar
• MooreKNMonkBJPatient counseling and management of symptoms during olaparib therapy for recurrent ovarian cancerOncologist201621895496327256873
   PubMed Web of Science ®Google Scholar
• Lynparza [homepage] Available from: https://www.lynparza.comAccessed June 27, 2018
   Google Scholar
• SakaiWSwisherEMJacquemontCFunctional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinomaCancer Res200969166381638619654294
   PubMed Web of Science ®Google Scholar
• SwisherEMSakaiWKarlanBYSecondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistanceCancer Res20086882581258618413725
   PubMed Web of Science ®Google Scholar
• WurzerGHercegZWesierska-GadekJIncreased resistance to anticancer therapy of mouse cells lacking the poly(ADP-ribose) polymerase attributable to up-regulation of the multidrug resistance gene product P-glycoproteinCancer Res200060154238424410945636
   PubMed Web of Science ®Google Scholar
• BuntingSFCallénEWongN53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaksCell2010141224325420362325
   PubMed Web of Science ®Google Scholar